盐酸利托君治疗先兆早产的临床观察  

Clinical observation of ritodrine hydrochloride in the treatment of threatened premature labor

作　　者：颜碧明[1] 

机构地区：[1]广东省茂名市妇幼保健院妇产科,广东茂名525000

出　　处：《中国当代医药》2014年第10期191-192,195,共3页China Modern Medicine

摘　　要：目的观察盐酸利托君治疗先兆早产的临床效果。方法将2011年1月～2013年12月在本院确诊的106例先兆早产患者按病床奇偶数分为两组，奇数组为A组，采用盐酸利托君治疗，偶数组为B组，采用硫酸镁治疗。其他治疗方法相同。观察分析两组的临床效果。结果A组有效率高于B组，产后不良反应发生率低于B组．差异有统计学意义（P〈0．01）；新生儿疾病发生率低于B组，差异有统计学意义（P〈0．05）；显效时间、累计用药时间短于B组，延长妊娠的时间长于B组，产后出血量少于B组，新生儿平均体重和Apgar评分高于B组，差异有统计学意义（P〈0．05）。结论盐酸利托君用于治疗先兆早产有效率高，抑制宫缩起效快，可有效延长妊娠时间．不良反应发生率低，作为先兆早产的首选药物值得临床推广应用。Objective To investigate the effect of ritodrine hydrochloride in the treatment of threatened premature la- bor. Methods 106 cases of patients with threatened premature labor diagnosed in our hospital from January 2011 to December 2013 were divided into two groups according to the number of beds parity,the odd number was as group A, even number was as group B,ritodrine hydrochloride was given to group A,magnesium sulfate was given to group B,and other treatment method was same.The clinical efficacy of two groups was compared.Results The effective rate of group A was higher than that of group B,postpartum incidence of adverse reaction was lower than that of group B,the differ- ence was significant （P〈0.01）; the incidence of neonatal disease was lower than that of group B,the difference was sig- nificant （P〈0.05）; markedly time,total treatment time was shorter than that of group B,extension time of pregnancy was longer than that of group B,postpartum hemorrhage was less than that of group B,the average newborn weight and Apgar score was higher than that of group B,the difference was significant （P〈O.05）.Conclusion Ritodrine hydrochloride for the treatment of threatened premature labor has high efficiency,rapid onset of inhibition of uterine contractions,which can effectively extend the time of pregnancy,the incidence of adverse reactions is low,as the drug of choice for threat- ened preterm labor is worthy of clinical application.

关 键 词：盐酸利托君 先兆早产 硫酸镁 临床效果 

分 类 号：R714.21[医药卫生—妇产科学]